Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Deutenzalutamide - Hinova Pharmaceuticals

X
Drug Profile

Deutenzalutamide - Hinova Pharmaceuticals

Alternative Names: Deuterated enzalutamide; Enzalutamide deuterated; HC 1119

Latest Information Update: 30 Aug 2024

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Hinova pharmaceuticals
  • Class Antineoplastics; Benzamides; Fluorinated hydrocarbons; Fluorobenzenes; Imidazoles; Imidazolidines; Nitriles; Organic deuterium compounds; Small molecules; Thiones
  • Mechanism of Action Androgen receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preregistration Prostate cancer
  • Phase III COVID 2019 infections
  • No development reported Breast cancer

Most Recent Events

  • 15 Aug 2024 Hinova Pharmaceuticals terminates phase-III clinical trials in Prostate cancer (First-line therapy, Hormone refractory, Metastatic disease) in Australia, Austria, US, Netherlands, Canada, Belgium, Denmark, Denmark, Finland, France, Germany, Italy, Poland, Russia, Spain, United Kingdom (PO) due to various factors including prolonged duration and enrollment challenges (EudraCT2019-001144-22) (NCT03850795)
  • 10 Jul 2023 Preregistration for Prostate cancer (Hormone refractory, Metastatic disease, Second-line therapy or greater) in China (PO) (Hinova Pharmaceuticals, pipeline July 2023)
  • 02 Jun 2023 Efficacy and adverse events data from a phase III trial in Prostate cancer presented at the 59th Annual Meeting of the American Society of Clinical Oncology (ASCO-2023)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top